Neuberger Berman Group’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.97M Sell
40,652
-3,169
-7% -$616K 0.01% 869
2025
Q4
$7.6M Sell
43,821
-474,675
-92% -$86.4M 0.01% 868
2025
Q3
$98.8M Sell
518,496
-197,828
-28% -$35.1M 0.07% 340
2025
Q2
$129M Buy
716,324
+79,801
+13% +$13.9M 0.1% 253
2025
Q1
$108M Buy
636,523
+570,785
+868% +$93.8M 0.09% 272
2024
Q4
$9.92M Buy
65,738
+6,227
+10% +$969K 0.01% 807
2024
Q3
$9.24M Buy
59,511
+331
+0.6% +$49.4K 0.01% 813
2024
Q2
$8.1M Buy
59,180
+24,832
+72% +$3.4M 0.01% 807
2024
Q1
$4.57M Buy
34,348
+2,037
+6% +$264K ﹤0.01% 951
2023
Q4
$4.46M Sell
32,311
-3,621
-10% -$476K ﹤0.01% 941
2023
Q3
$4.38M Buy
35,932
+4,695
+15% +$626K ﹤0.01% 915
2023
Q2
$4.39M Sell
31,237
-14,181
-31% -$1.95M ﹤0.01% 918
2023
Q1
$6.43M Buy
45,418
+20,522
+82% +$2.94M 0.01% 828
2022
Q4
$3.89M Buy
24,896
+936
+4% +$135K ﹤0.01% 917
2022
Q3
$2.99M Sell
23,960
-18,843
-44% -$2.48M ﹤0.01% 997
2022
Q2
$5.74M Buy
42,803
+1,210
+3% +$165K 0.01% 858
2022
Q1
$5.73M Buy
41,593
+6,479
+18% +$903K ﹤0.01% 928
2021
Q4
$5.84M Buy
35,114
+11,784
+51% +$1.79M ﹤0.01% 938
2021
Q3
$3.22M Buy
23,330
+13,396
+135% +$1.96M ﹤0.01% 1056
2021
Q2
$1.23M Sell
9,934
-12,166
-55% -$1.59M ﹤0.01% 1285
2021
Q1
$2.76M Sell
22,100
-125,226
-85% -$15.4M ﹤0.01% 1078
2020
Q4
$17.6M Sell
147,326
-8,500
-5% -$1.04M 0.02% 676
2020
Q3
$17.8M Buy
155,826
+25,810
+20% +$3.05M 0.02% 610
2020
Q2
$14.8M Buy
130,016
+72,778
+127% +$7.72M 0.02% 631
2020
Q1
$4.6M Buy
57,238
+48,037
+522% +$4.97M 0.01% 802
2019
Q4
$982K Sell
9,201
-2,912
-24% -$304K ﹤0.01% 1162
2019
Q3
$1.3M Buy
12,113
+5,526
+84% +$567K ﹤0.01% 1097
2019
Q2
$670K Sell
6,587
-1,210
-16% -$116K ﹤0.01% 1235
2019
Q1
$701K Sell
7,797
-28,898
-79% -$2.5M ﹤0.01% 1190
2018
Q4
$3.06M Buy
36,695
+10,504
+40% +$985K ﹤0.01% 910
2018
Q3
$2.83M Sell
26,191
-37,639
-59% -$4.13M ﹤0.01% 982
2018
Q2
$7.14M Buy
63,830
+35,169
+123% +$3.66M 0.01% 862
2018
Q1
$2.97M Buy
28,661
+1,117
+4% +$114K ﹤0.01% 957
2017
Q4
$2.78M Sell
27,544
-10,002
-27% -$948K ﹤0.01% 965
2017
Q3
$3.52M Buy
37,546
+264
+0.7% +$28K ﹤0.01% 909
2017
Q2
$4.14M Buy
37,282
+189
+0.5% +$20K 0.01% 896
2017
Q1
$3.64M Sell
37,093
-2,663
-7% -$254K ﹤0.01% 904
2016
Q4
$3.65M Buy
39,756
+1,569
+4% +$135K ﹤0.01% 904
2016
Q3
$3.23M Buy
38,187
+34,477
+929% +$2.9M ﹤0.01% 903
2016
Q2
$302K Buy
3,710
+277
+8% +$21.1K ﹤0.01% 1362
2016
Q1
$245K Sell
3,433
-162,645
-98% -$10.9M ﹤0.01% 1396
2015
Q4
$11.8M Sell
166,078
-147,926
-47% -$9.95M 0.02% 731
2015
Q3
$19.3M Buy
314,004
+3,866
+1% +$270K 0.02% 639
2015
Q2
$22.5M Sell
310,138
-27
-0% -$1.99K 0.03% 664
2015
Q1
$23.8M Buy
+310,165
New +$22.2M 0.03% 635
2014
Q3
Sell
-5,100
Closed -$299K 1654
2014
Q2
$299K Sell
5,100
-3,568
-41% -$209K ﹤0.01% 1504
2014
Q1
$502K Buy
8,668
+797
+10% +$42.7K ﹤0.01% 1337
2013
Q4
$421K Sell
7,871
-170
-2% -$10.1K ﹤0.01% 1372
2013
Q3
$497K Buy
8,041
+4,547
+130% +$272K ﹤0.01% 1315
2013
Q2
$212K Buy
+3,494
New +$208K ﹤0.01% 1479

Other funds holding DGX

Neuberger Berman Group's DGX Position: Q1 2026 in Review

Neuberger Berman Group reduced its Quest Diagnostics (DGX) stake by 7.2% in Q1 2026, selling an estimated $616K and leaving 40,652 shares worth $7.97M. The position accounts for 0.01% of the portfolio, ranked #869.

Neuberger Berman Group first reported a position in DGX in Q2 2013 and has held it in 50 quarters since. The position peaked at $129M in Q2 2025. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Neuberger Berman Group held 40,652 shares of Quest Diagnostics worth $7.97M as of Q1 2026.
  • Neuberger Berman Group sold 3,169 Quest Diagnostics shares in Q1 2026, an estimated $616K.
  • Quest Diagnostics made up 0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #869 holding.
  • Neuberger Berman Group first reported a position in Quest Diagnostics in Q2 2013 and has held it in 50 quarters since.
  • Neuberger Berman Group's Quest Diagnostics position peaked at $129M in Q2 2025.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.